164 related articles for article (PubMed ID: 37121707)
1. [Discovery of RANKL and the current and future impact of its research].
Yasuda H
Nihon Yakurigaku Zasshi; 2023; 158(3):247-252. PubMed ID: 37121707
[TBL] [Abstract][Full Text] [Related]
2. [The mechanism of anti-RANKL antibody in the treatment of metabolic bone diseases including osteoporosis - possible applications of anti-RANKL antibody to the treatment of cancer patients].
Yasuda H
Nihon Yakurigaku Zasshi; 2019; 153(1):11-15. PubMed ID: 30643086
[TBL] [Abstract][Full Text] [Related]
3. Discovery of the RANKL/RANK/OPG system.
Yasuda H
J Bone Miner Metab; 2021 Jan; 39(1):2-11. PubMed ID: 33389131
[TBL] [Abstract][Full Text] [Related]
4. Anti-RANKL antibody was approved for the treatment of osteoporosis in Japan.
Yasuda H
Nihon Rinsho Meneki Gakkai Kaishi; 2013; 36(4):209-16. PubMed ID: 23994799
[TBL] [Abstract][Full Text] [Related]
5. [Anti-RANKL antibody].
Omiya T; Tanaka S
Nihon Rinsho; 2015 Oct; 73(10):1690-5. PubMed ID: 26529931
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of bone metastasis by denosumab, the human monoclonal neutralizing antibody to RANKL].
Yoneda T
Nihon Rinsho; 2012 Dec; 70(12):2165-71. PubMed ID: 23259391
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of RANK/RANKL signal transduction pathway: a promising approach for osteoporosis treatment.
Bai YD; Yang FS; Xuan K; Bai YX; Wu BL
Med Hypotheses; 2008 Aug; 71(2):256-8. PubMed ID: 18445511
[TBL] [Abstract][Full Text] [Related]
8. The RANKL-RANK Axis: A Bone to Thymus Round Trip.
Sobacchi C; Menale C; Villa A
Front Immunol; 2019; 10():629. PubMed ID: 30984193
[TBL] [Abstract][Full Text] [Related]
9. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL.
Kostenuik PJ; Nguyen HQ; McCabe J; Warmington KS; Kurahara C; Sun N; Chen C; Li L; Cattley RC; Van G; Scully S; Elliott R; Grisanti M; Morony S; Tan HL; Asuncion F; Li X; Ominsky MS; Stolina M; Dwyer D; Dougall WC; Hawkins N; Boyle WJ; Simonet WS; Sullivan JK
J Bone Miner Res; 2009 Feb; 24(2):182-95. PubMed ID: 19016581
[TBL] [Abstract][Full Text] [Related]
10. Receptor-Activator of Nuclear KappaB Ligand Expression as a New Therapeutic Target in Primary Bone Tumors.
Yamagishi T; Kawashima H; Ogose A; Ariizumi T; Sasaki T; Hatano H; Hotta T; Endo N
PLoS One; 2016; 11(5):e0154680. PubMed ID: 27163152
[TBL] [Abstract][Full Text] [Related]
11. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
Dempster DW; Lambing CL; Kostenuik PJ; Grauer A
Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
[TBL] [Abstract][Full Text] [Related]
12. [Control of bone resorption by RANKL-RANK system].
Harada S; Takahashi N
Clin Calcium; 2011 Aug; 21(8):1121-30. PubMed ID: 21814016
[TBL] [Abstract][Full Text] [Related]
13. Cell-based assay strategy for identification of motif-specific RANK signaling pathway inhibitors.
Chen T; Feng X
Assay Drug Dev Technol; 2006 Aug; 4(4):473-82. PubMed ID: 16945019
[TBL] [Abstract][Full Text] [Related]
14. Stimulation of bone formation in cortical bone of mice treated with a receptor activator of nuclear factor-κB ligand (RANKL)-binding peptide that possesses osteoclastogenesis inhibitory activity.
Furuya Y; Inagaki A; Khan M; Mori K; Penninger JM; Nakamura M; Udagawa N; Aoki K; Ohya K; Uchida K; Yasuda H
J Biol Chem; 2013 Feb; 288(8):5562-71. PubMed ID: 23319583
[TBL] [Abstract][Full Text] [Related]
15. Induction of chondrogenesis with a RANKL-binding peptide, WP9QY, in vitro and in vivo in a rabbit model.
Furuya Y; Mera H; Itokazu M; Terai S; Nakamura H; Wakitani S; Yasuda H
Biochem Biophys Res Commun; 2022 Apr; 602():98-104. PubMed ID: 35259590
[TBL] [Abstract][Full Text] [Related]
16. Skeletal and extraskeletal actions of denosumab.
Sinningen K; Tsourdi E; Rauner M; Rachner TD; Hamann C; Hofbauer LC
Endocrine; 2012 Aug; 42(1):52-62. PubMed ID: 22581255
[TBL] [Abstract][Full Text] [Related]
17. A review of denosumab for the treatment of osteoporosis.
Miyazaki T; Tokimura F; Tanaka S
Patient Prefer Adherence; 2014; 8():463-71. PubMed ID: 24748775
[TBL] [Abstract][Full Text] [Related]
18. Do RANKL inhibitors (denosumab) affect inflammation and immunity?
Ferrari-Lacraz S; Ferrari S
Osteoporos Int; 2011 Feb; 22(2):435-46. PubMed ID: 20571772
[TBL] [Abstract][Full Text] [Related]
19. Osteoclast Recycling and the Rebound Phenomenon Following Denosumab Discontinuation.
Kim AS; Girgis CM; McDonald MM
Curr Osteoporos Rep; 2022 Dec; 20(6):505-515. PubMed ID: 36201122
[TBL] [Abstract][Full Text] [Related]
20. Unexpected Bone Formation Produced by RANKL Blockade.
Portal-Núñez S; Mediero A; Esbrit P; Sánchez-Pernaute O; Largo R; Herrero-Beaumont G
Trends Endocrinol Metab; 2017 Oct; 28(10):695-704. PubMed ID: 28733136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
